A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington’s disease

Background Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin ( HTT ) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functi...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neuroinflammation Vol. 19; no. 1; pp. 56 - 17
Main Authors:	Chen, Kai-Po, Hua, Kuo-Feng, Tsai, Fu-Ting, Lin, Ting-Yu, Cheng, Chih-Yuan, Yang, Ding-I., Hsu, Hsien-Ta, Ju, Tz-Chuen
Format:	Journal Article
Language:	English
Published:	London BioMed Central 26.02.2022 BioMed Central Ltd BMC
Subjects:	Animals Biomedical and Life Sciences Biomedicine Disease Models, Animal Genetic aspects Huntington Disease - drug therapy Huntington Disease - genetics Huntington Disease - metabolism Huntington's chorea Huntington’s disease (HD) Immunology Inflammasomes - therapeutic use Interleukin‐1β (IL‐1β) Male Mice Mice, Transgenic Mutated huntingtin (mHTT) Neurobiology Neurodegenerative Diseases Neurology Neuroprotection Neurosciences NLR Family, Pyrin Domain-Containing 3 Protein - metabolism Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Patient outcomes Prevention Taiwan Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Huntington’s disease (HD) Interleukin‐1β (IL‐1β) Mutated huntingtin (mHTT)
ISSN:	1742-2094, 1742-2094
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!